The Nobel Prize-winning scientific innovation underlying the COVID-19 vaccine proved to be a notable financial boon for the ...
Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.
The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...
BioNTech (BNTX) stock slipped after signing $1B deals with NIH and the University of Pennsylvania to resolve COVID vaccine ...
BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University ...
In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the University ...
Concurrently, BioNTech (BNTX) announced a settlement agreement worth $467M with Penn to resolve a lawsuit filed by the university over royalty claims related to the COVID-19 shot. The deal ...
Pfizer has agreed to reimburse BioNTech for $364.5 million of the claimed royalties paid to NIH and $170.0 million of the claimed royalties paid to the University of Pennsylvania. Write to Dean Seal ...
The settlements will see BioNTech pay $791.5 million to NIH and $467 million to Penn, with Pfizer (PFE), its vaccine partner, reimbursing part of these payments. The dispute stemmed from claims by ...